Hematemesis as the initial manifestation of pancreatic cancer directly invading the duodenum: a case report

Hirai, Ryuji; Negoro, Yuji; Hyodo, Tsuyoshi; Miyake, Takayoshi; Kunitomo, Tadayoshi; Muraoka, Takayuki; Tsuji, Hisashi; Nawa, S

doi:10.2958/suizo.23.172

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although pancreatic cancer is a rare cause of gastrointestinal bleeding, endoscopic approaches are not really suitable for stopping bleeding caused by pancreatic cancer invasion due to the associated duodenal narrowing, and to the fact that the cancer tissue itself is fragile. Moreover, once bleeding has occurred, it often recurs, resulting in serious blood loss 5–7 . Failure of hemostasis results in a poor prognosis because it is difficult to continue cancer chemotherapy due to gastrointestinal bleeding.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, once bleeding has occurred, it often recurs, resulting in serious blood loss. 5 , 6 , 7 Failure of hemostasis results in a poor prognosis because it is difficult to continue cancer chemotherapy due to gastrointestinal bleeding. Nowadays, a covered self‐expandable metal stent (CSEMS) is used to stop refractory bleeding, particularly refractory variceal bleeding.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Utility of a partially covered metal stent for salvage sealing therapy for bleeding caused by duodenal invasion of pancreatobiliary cancers: Case series

et al. 2023

View full text Add to dashboard Cite

Pancreatobiliary cancer‐related gastrointestinal bleeding caused by duodenal invasion can be a life‐threatening condition that is hard to control. It is unclear whether a covered self‐expandable metal stent (CSEMS) is useful for hemostasis of bleeding related to advanced pancreatobiliary cancer. The aim of this study was to evaluate the utility of a CSEMS for hemostasis of bleeding caused by duodenal invasion of pancreatobiliary cancer. Between January 2020 and January 2022, seven patients in whom a duodenal CSEMS was inserted to control pancreatobiliary cancer‐related bleeding were enrolled. The technical and clinical success rates with respect to hemostasis, procedure time, and adverse events were assessed. All patients were inoperable cases (six with pancreatic cancer [five, stage IV; one, stage III]; and one with gallbladder cancer [stage IV]) in whom CSEMs were inserted to treat refractory bleeding caused by cancer invasion. Hemostasis was achieved in all cases (100% [7/7]). The mean procedure time was 17 ± 7.9 min. There were no adverse events, including migration and rebleeding. No rebleeding occurred up until the time of death in any of the cases (mean follow‐up period, 73 ± 27 days). Deployment of duodenal CSEMS is a useful salvage therapy for bleeding caused by advanced pancreatobiliary cancer invasion.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Utility of a partially covered metal stent for salvage sealing therapy for bleeding caused by duodenal invasion of pancreatobiliary cancers: Case series

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Some researchers reported that pancreatic tumors usually have the character of the infiltrative growth, but seldom cause bleeding because of their ischemic nature [ 4 ]. On the other hand, once bleeding has occurred, it often recurs, resulting in serious massive blood loss [ 5 , 6 , 7 ].…”

Section: Discussionmentioning

confidence: 99%

Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1

Takada¹,

Ioka²,

Sueyoshi³

et al. 2014

Case Rep Gastroenterol

View full text Add to dashboard Cite

2.6% of pancreatic cancer patients have the primary manifestation of gastrointestinal bleeding. It is not feasible to stop the duodenal hemorrhage caused by the pancreatic cancer infiltration. A 43-year-old woman who was diagnosed as having pancreatic cancer with multiple hepatic metastases and duodenal infiltration was administered gemcitabine and S-1 combination therapy. During the chemotherapy, initially, bleeding occurred due to duodenal infiltration. However, we continued the chemotherapy and duodenal infiltration was markedly reduced in size and did not rebleed. Aggressive chemotherapy contributed to maintenance of performance status as well as improvement of quality of life for the patient.

show abstract

Hemorrhagic shock successfully treated with emergency pancreaticoduodenectomy for pancreatic carcinoma in radiochemotherapy: A case report

Wada¹,

Taniwaki²,

Yoshimoto³

et al. 2022

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Hematemesis as the initial manifestation of pancreatic cancer directly invading the duodenum: a case report

Cited by 3 publications

References 4 publications

Utility of a partially covered metal stent for salvage sealing therapy for bleeding caused by duodenal invasion of pancreatobiliary cancers: Case series

Utility of a partially covered metal stent for salvage sealing therapy for bleeding caused by duodenal invasion of pancreatobiliary cancers: Case series

Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1

Hemorrhagic shock successfully treated with emergency pancreaticoduodenectomy for pancreatic carcinoma in radiochemotherapy: A case report

Contact Info

Product

Resources

About